Orzaks İlaç (ORZAX) Fundamental Analysis
This page summarises the financial statements and the KapAI scorecard of Orzaks İlaç (ORZAX) in the İlaç ve Sağlık sector for the 2026/6 period. Figures are compiled from the company’s reported balance sheet and income statement, in millions of Turkish lira.
Company Information
- Company: Orzaks İlaç
- Ticker: ORZAX
- Sector: İlaç ve Sağlık
- Latest reporting period: 2026/6
KapAI Scorecard
Overall score: 2.5 / 5
- Profitability: 4.5 / 5
- Liquidity: 3.0 / 5
- Leverage: 1.3 / 5
- Efficiency: 1.0 / 5
Summary Income Statement (TRY million)
Period: 2026/6
| Item | 2026/6 | Previous | Change |
|---|---|---|---|
| Revenue | 4,526 | — | — |
| Gross Profit | 2,963 | — | — |
| Operating Profit | 1,251 | — | — |
| EBITDA | 0 | — | — |
| Net Monetary Position Gains | -172 | — | — |
| Net Profit for the Period | 306 | — | — |
Summary Balance Sheet (TRY million)
Period: 2026/6
| Item | 2026/6 | Previous | Change |
|---|---|---|---|
| Current Assets | 8,513 | — | — |
| Non-Current Assets | 1,599 | — | — |
| Total Assets | 10,112 | — | — |
| Current Liabilities | 5,458 | — | — |
| Non-Current Liabilities | 1,114 | — | — |
| Total Liabilities | 6,572 | — | — |